gadoquatrane - Profile
✉ Email this page to a colleague
What are the generic drug sources for gadoquatrane and what is the scope of freedom to operate?
Gadoquatrane
is the generic ingredient in one branded drug marketed by Bayer Healthcare and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Summary for gadoquatrane
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for gadoquatrane
Generic Entry Date for gadoquatrane*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for gadoquatrane
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | AMBELVIST | gadoquatrane | SOLUTION;INTRAVENOUS | 219627-001 | Jun 12, 2026 | RX | Yes | Yes | 10,722,601 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare | AMBELVIST | gadoquatrane | SOLUTION;INTRAVENOUS | 219627-001 | Jun 12, 2026 | RX | Yes | Yes | 10,137,209 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare | AMBELVIST | gadoquatrane | SOLUTION;INTRAVENOUS | 219627-001 | Jun 12, 2026 | RX | Yes | Yes | 11,944,690 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bayer Healthcare | AMBELVIST | gadoquatrane | SOLUTION;INTRAVENOUS | 219627-001 | Jun 12, 2026 | RX | Yes | Yes | 12,478,696 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
